Nautilus Biotechnology, Inc. (NAUT)

Nautilus Biotechnology Analyst Ratings

• Total Analysts: 3
• Consensus Rating: Hold
• Price Target: $3.58
• Upside: +347.72%

Ratings History

Filter results

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Matthew Sykes Goldman Sachs	Goldman Sachs	Hold → Strong Sell Downgrades $2.25 → $1.75	Hold → Strong Sell	Downgrades	$2.25 → $1.75	+118.86%	Dec 5, 2024
Subbu Nambi Guggenheim	Guggenheim	Strong Buy Initiates $6	Strong Buy	Initiates	$6	+650.38%	Jun 27, 2024
Tycho Peterson Jefferies	Jefferies	Strong Buy → Hold Initiates $5 → $3	Strong Buy → Hold	Initiates	$5 → $3	+275.19%	Jun 3, 2024
Tejas Savant Morgan Stanley	Morgan Stanley	Hold Reiterates $6	Hold	Reiterates	$6	+650.38%	Aug 3, 2023
Tejas Savant Morgan Stanley	Morgan Stanley	Hold Maintains $8 → $6	Hold	Maintains	$8 → $6	+650.38%	Aug 3, 2022
Matthew Sykes Goldman Sachs	Goldman Sachs	Hold Maintains $4 → $2	Hold	Maintains	$4 → $2	+150.13%	Aug 3, 2022
Matthew Sykes Goldman Sachs	Goldman Sachs	Hold Maintains $5 → $4	Hold	Maintains	$5 → $4	+400.25%	Jul 14, 2022
Matthew Sykes Goldman Sachs	Goldman Sachs	Hold Maintains $9 → $5	Hold	Maintains	$9 → $5	+525.31%	Apr 13, 2022
Tejas Savant Morgan Stanley	Morgan Stanley	Hold Initiates $8	Hold	Initiates	$8	+900.50%	Jan 6, 2022
Max Masucci Cowen & Co.	Cowen & Co.	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Nov 2, 2021
Matthew Sykes Goldman Sachs	Goldman Sachs	Hold Initiates $10	Hold	Initiates	$10	+1,150.63%	Aug 4, 2021
Brandon Couillard Jefferies	Jefferies	Strong Buy Initiates $13	Strong Buy	Initiates	$13	+1,525.81%	Jul 13, 2021